Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. RGC
stocks logo

RGC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Regencell Bioscience Holdings Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RGC News & Events

Events Timeline

(ET)
2025-12-04
12:10:00
Regencell Bioscience Shares Rise 23.7% to $16.09
select
2025-11-03 (ET)
2025-11-03
13:15:11
Regencell raises significant concerns regarding its ability to remain operational.
select
link
2025-11-03
09:45:41
Regencell Bioscience Reports DOJ Investigation into Share Trading Activities
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
12-02Benzinga
Simulations Plus Reports Impressive Q4 Performance, Alongside Credo Technology Group, United Natural Foods, Boeing, and Other Major Stocks Rising on Tuesday
  • U.S. Stock Market Performance: U.S. stocks rose on Tuesday, with the Dow Jones gaining approximately 150 points, driven by strong performances from several companies.

  • Simulations Plus Earnings Report: Simulations Plus Inc. saw a significant share price increase of 15.7% after reporting quarterly earnings of 10 cents per share, surpassing analyst expectations of a loss.

  • Notable Stock Gains: Other companies like MongoDB Inc. and Credo Technology Group also experienced substantial gains, with MongoDB rising 25.1% and Credo Technology up 19.2% following positive financial results and raised guidance.

  • Boeing's Positive Outlook: Boeing Co. shares increased by 8.4% after announcing expectations for higher deliveries of its 737 and 787 models in FY26, alongside plans to complete its Spirit acquisition this year.

[object Object]
Preview
7.0
11-22Globenewswire
Bragar Eagel & Squire, P.C. Ongoing Investigations into Regencell, Beyond Meat, Alvotech, and Camping World for Stockholders; Invites Investors to Reach Out to the Firm
  • Regencell Bioscience Holdings Investigation: Regencell is under investigation by the U.S. Department of Justice for potential violations related to its stock trading, leading to an 18.56% drop in its stock price following the announcement.

  • Beyond Meat's Impairment Charge: Beyond Meat announced a significant non-cash impairment charge and delayed its earnings report, resulting in a 23% decline in its stock price.

  • Alvotech's FDA Response: Alvotech received a Complete Response Letter from the FDA regarding its biologics license application, causing its stock to plummet by 34.25%.

  • Camping World Holdings Misstatements: Camping World disclosed prior misstatements in its financial reporting, leading to a 24.79% decrease in its stock price after revising its deferred tax assets.

[object Object]
Preview
7.0
11-20PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC
  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Regencell Bioscience Holdings Limited and its officers or directors, urging affected investors to reach out for assistance.

  • DOJ Subpoena: Regencell disclosed receiving a subpoena from the U.S. Department of Justice, which is investigating trading activities related to its Ordinary Shares, leading to concerns about significant legal costs and potential financial penalties.

  • Stock Price Impact: Following the announcement of the DOJ investigation, Regencell's stock price dropped by 18.56%, closing at $13.56 per share on November 3, 2025.

  • Pomerantz LLP Background: Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has secured substantial damages for class members over its 85-year existence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Regencell Bioscience Holdings Ltd (RGC) stock price today?

The current price of RGC is 16 USD — it has increased 22.98 % in the last trading day.

arrow icon

What is Regencell Bioscience Holdings Ltd (RGC)'s business?

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

arrow icon

What is the price predicton of RGC Stock?

Wall Street analysts forecast RGC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Regencell Bioscience Holdings Ltd (RGC)'s revenue for the last quarter?

Regencell Bioscience Holdings Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Regencell Bioscience Holdings Ltd (RGC)'s earnings per share (EPS) for the last quarter?

Regencell Bioscience Holdings Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Regencell Bioscience Holdings Ltd (RGC)'s fundamentals?

The market is revising No Change the revenue expectations for RGC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 20.66%.
arrow icon

How many employees does Regencell Bioscience Holdings Ltd (RGC). have?

Regencell Bioscience Holdings Ltd (RGC) has 12 emplpoyees as of December 05 2025.

arrow icon

What is Regencell Bioscience Holdings Ltd (RGC) market cap?

Today RGC has the market capitalization of 7.86B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free